Weekly Digest - Jan 2024
CAR-T Digest - August 2020
CAR-T Digest - August 2020
CAR-T Digest - August 2020
CAR-T Digest - August 2020
Weekly Digest - Jan 2024
22 Jan 2024: Gilead’s Trodelvy fails to extend survival in lung cancer study, prompting selloff
- Gilead faces a setback as its phase 3 trial for Trodelvy in metastatic non-small cell lung cancer (NSCLC), fails to significantly extend patient lives compared to chemotherapy
- Despite the trial’s failure to meet the primary endpoint, Gilead expresses continued confidence in Trodelvy’s potential based on the overall data
- Gilead shares tumble about 10% after the trial flop
- Competition, particularly from Enhertu in the HER2-low breast cancer category, poses a challenge to Trodelvy’s market share, emphasizing the importance of expanding its use in NSCLC
